Identifying and Treating Familial Hypercholesterolemia

Details & Video

Program Time: 30 minutes - includes presentation and interactivity
Accreditation-CME Credits: Accreditation for this activity has expired; however, Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.
Target Audience: General Practitioners
Program Preview
Click image above to play the program preview.

Overview & Objectives

Identifying and Treating Familial Hypercholesterolemia

Target Audience: General Practitioners.

By participating in this educational program, health care providers will be able to:
  1. Examine the prevalence and risk associated with FH
  2. Review the strategies to recognize potential FH patients
  3. Identify optimal treatment strategies for FH



Planning Committee & Faculty

Planning Committee & Faculty

Rob Hegele
Faculty
Rob Hegele
MD, FRCPC, FACP, FAHA, FCAHS, FCCS
London, Ontario

Jacob J. Wolfe Distinguished Medical Research Chair in Human Gene Function
Martha G. Blackburn Chair in Cardiovascular Research
Director, London Regional Genomics Centre
Scientist, Molecular Medicine, Robarts Research Institute
Distinguished University Professor, Departments of Medicine (Division of Endocrinology) and Biochemistry, Western University
View disclosures

Milan Gupta
Planning Committee
Milan Gupta
MD, FRCPC, FCCS
Brampton, ON

Associate Clinical Professor of Medicine,
McMaster University

Medical Director
Canadian Collaborative Research Network

View disclosures

Jeffrey Habert
Planning Committee
Jeffrey Habert
MD, CCFP, FCFP
Toronto, Ontario

Assistant Professor,
University of Toronto,
Dept. of Family and Community Medicine

View disclosures

Daniel Ngui
Planning Committee
Daniel Ngui
B. Sc., PT, M.D., FCMF
Vancouver, BC

Clinical Associate Professor
University of British Columbia

Medical Director
Fraser Street Medical

View disclosures

Marla Shapiro
Planning Committee
Marla Shapiro
C.M., M.D.C.M., CMFC, M. Sc. S., FRCPC, FCMF, NCMP
Toronto, Ontario

Professor, University of Toronto
Department of Family and Community Medicine

University Health Network
North York General, Mount Sinai

View disclosures

Agenda

Agenda

Program ChapterDuration
(Min:Sec)
Introduction2:02
Patient case5:34
Prevalence of FH4:39
Associated CV risk4:03
Identifying potential FH patient2:29
Treatment strategies4:31
Practical considerations and summary2:08


Sponsorship

CCRN sm

This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and is supported through an educational grant received from:

Amgen Canada

Links & Resources

Links & Resources:

  • Yuan et al. CMAJ 2006; 174:1124-9
  • Adapted from Nordestgaard BG et al. Eur Heart J 2013;34:3478-90a
  • Adapted from Austin MA et al. Am J Epidemiol 2004;160:421-9; Genest J et al. Can J Cardiol 2014;30:1471-81
  • Ruel, I et al. in review
  • Genest J. et al. Can J Cardiol. 2014; 30:1471-81
  • Defesche JC et al. Nat. Rev. Dis. Primers 2017 doi:10.1038/nrdp.2017.93
  • Adapted from Kastelein, JJP et al. As presented during ESC Congress 2015, Abstract 5772.
  • Raal F et al. Lancet 2015;385:331-40